<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01752023</url>
  </required_header>
  <id_info>
    <org_study_id>J1230</org_study_id>
    <secondary_id>NA_00067809</secondary_id>
    <nct_id>NCT01752023</nct_id>
  </id_info>
  <brief_title>A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.</brief_title>
  <acronym>NA_00067809</acronym>
  <official_title>A Randomized Phase II Study of SUBATM-itraconazole With Cisplatin/Gemcitabine in Patients With Previously Untreated Metastatic Squamous Non-Small Cell Lung Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Response rates.&#xD;
&#xD;
      Changes in tumor blood flow.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the objective response rates of cisplatin and gemcitabine with or without&#xD;
      SUBATM-itraconazole in patients with chemotherapy-na√Øve metastatic squamous non-small cell&#xD;
      lung cancer.&#xD;
&#xD;
      To assess the changes in tumor blood flow as measured by contrast enhanced MRI scanning in&#xD;
      patients with metastatic squamous non-small cell lung cancer treated with cisplatin and&#xD;
      gemcitabine with or without SUBATM-itraconazole.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low Accrual&#xD;
  </why_stopped>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rates</measure>
    <time_frame>6 weeks</time_frame>
    <description>Per response evaluation criteria in solid tumors criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Blood Flow.</measure>
    <time_frame>6 weeks.</time_frame>
    <description>To assess the changes in tumor blood flow as measured by contrast enhanced MRI scanning in patients with metastatic squamous non-small cell lung cancer treated with cisplatin and gemcitabine with or without SUBATM-itraconazole.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Time to Progression</measure>
    <time_frame>2 years.</time_frame>
    <description>To determine the median time to progression and median duration of survival of patients with metastatic squamous non-small cell lung cancer treated with cisplatin and gemcitabine with or without SUBATM-itraconazole.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects</measure>
    <time_frame>2 years.</time_frame>
    <description>To characterize the adverse effects of cisplatin and gemcitabine with or without SUBATM-itraconazole in this patient population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itraconazole Exposure Parameters</measure>
    <time_frame>2 years.</time_frame>
    <description>To correlate itraconazole exposure parameters with median time to progression and median survival in this patient population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Necrosis</measure>
    <time_frame>2 years.</time_frame>
    <description>To assess changes in tumor necrosis in response to cisplatin and gemcitabine with or without SUBATM-itraconazole.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Non-small Cell Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Cisplatin + Gemcitabine with SUBATM-itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SUBATM-itraconazole 200 mg BID, Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then SUBATM-itraconazole 200 mg BID alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin + Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B = Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then Best supportive care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin + Gemcitabine with SUBATM-itraconazole</intervention_name>
    <description>Experimental Arm</description>
    <arm_group_label>Cisplatin + Gemcitabine with SUBATM-itraconazole</arm_group_label>
    <other_name>SUBATM-itraconazole + Cisplatin and Gemcitabine for 6 cycles followed by SUBATM-itraconazole alone.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin + Gemcitabine</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>Cisplatin + Gemcitabine</arm_group_label>
    <other_name>Cisplatin and Gemcitabine for 6 cyles followed by Best supportive care.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stage IV squamous cell lung cancer, with no prior systemic chemotherapy.&#xD;
&#xD;
          -  Patients who have received prior adjuvant chemotherapy for early-stage lung cancer are&#xD;
             eligible if at least 6 months have elapsed from completion of that treatment.&#xD;
&#xD;
          -  Patients whose tumors contain mixed non-small cell histologies are eligible if&#xD;
             squamous carcinoma is the predominant histology. Mixed tumors with small cell&#xD;
             anaplastic elements are not eligible.&#xD;
&#xD;
          -  Patient must have measurable disease per RECIST 1.1 (defined in section 9.1.2).&#xD;
&#xD;
          -  Patients with previous radiotherapy as definitive therapy for locally advanced&#xD;
             non-small cell lung cancer are eligible, as long as the recurrence is outside the&#xD;
             original radiation therapy port. Radiation therapy must have been completed greater&#xD;
             than or equal to 2 weeks prior to enroll in this study.&#xD;
&#xD;
          -  Age greater than or equal to 18 years. Because no dosing or adverse event data are&#xD;
             currently available on the use of itraconazole or SUBATM-itraconazole in combination&#xD;
             with gemcitabine/cisplatin in patients under 18 years of age, such patients are&#xD;
             excluded from this study. Squamous cell lung cancer is exceedingly rare in children.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status 0 - 1.&#xD;
&#xD;
          -  Patients must have adequate organ and marrow function.&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for&#xD;
             the duration of study participation. Should a woman become pregnant or suspect she is&#xD;
             pregnant while participating in this study, she should inform her treating physician&#xD;
             immediately.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with gemcitabine, cisplatin (except in the adjuvant setting),&#xD;
             itraconazole or SUBATM-itraconazole.&#xD;
&#xD;
          -  Uncontrolled brain metastases. Patients with brain metastases must have stable&#xD;
             neurologic status following local therapy (surgery or radiation) for at least 2 weeks,&#xD;
             and must be without neurologic dysfunction that would confound the evaluation of&#xD;
             neurologic and other adverse events.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to itraconazole, SUBATM-itraconazole, gemcitabine, cisplatin or other&#xD;
             agents used in the study.&#xD;
&#xD;
          -  Itraconazole is a strong CYP3A4 inhibitor and may increase plasma concentrations of&#xD;
             drugs metabolized by this pathway. Co-administration of cisapride, midazolam,&#xD;
             pimozide, quinidine, lovastatin, simvastatin, triazolam, dofetilide, or&#xD;
             levacetylmethadol (levomethadyl) with SUBATM-itraconazole or itraconazole is&#xD;
             contraindicated.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Pregnant women are excluded from this study because itraconazole is Class C agent and&#xD;
             both gemcitabine and cisplatin are Class D agents, with the potential for teratogenic&#xD;
             or abortifacient effects. Because there is an unknown but potential risk for adverse&#xD;
             events in nursing infants secondary to treatment of the mother with&#xD;
             SUBATM-itraconazole and gemcitabine/cisplatin, breastfeeding should be discontinued if&#xD;
             the mother is to be treated on this protocol.&#xD;
&#xD;
          -  HIV-positive patients on combination antiretroviral therapy are ineligible because of&#xD;
             the potential for pharmacokinetic interactions with SUBATM-itraconazole, gemcitabine,&#xD;
             or cisplatin with these essential mediations.&#xD;
&#xD;
          -  Medical contra-indication to MRI (e.g. gadolinium allergy, or severe claustrophobia).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Ettinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bayview Medical Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University, SKCCC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>December 14, 2012</study_first_submitted>
  <study_first_submitted_qc>December 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2012</study_first_posted>
  <results_first_submitted>March 6, 2017</results_first_submitted>
  <results_first_submitted_qc>April 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2017</results_first_posted>
  <last_update_submitted>September 18, 2018</last_update_submitted>
  <last_update_submitted_qc>September 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cisplatin + Gemcitabine With SUBATM-itraconazole</title>
          <description>SUBATM-itraconazole 200 mg BID, Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then SUBATM-itraconazole 200 mg BID alone.&#xD;
Arm A: Experimental Arm</description>
        </group>
        <group group_id="P2">
          <title>Cisplatin + Gemcitabine</title>
          <description>Arm B = Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then Best supportive care.&#xD;
Arm B: Active Comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A</title>
          <description>SUBATM-itraconazole 200 mg BID, Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then SUBATM-itraconazole 200 mg BID alone.&#xD;
Arm A: Experimental Arm</description>
        </group>
        <group group_id="B2">
          <title>Arm B</title>
          <description>Arm B = Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then Best supportive care.&#xD;
Arm B: Active Comparator</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="52" upper_limit="66"/>
                    <measurement group_id="B2" value="67" lower_limit="67" upper_limit="67"/>
                    <measurement group_id="B3" value="66" lower_limit="52" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rates</title>
        <description>Per response evaluation criteria in solid tumors criteria</description>
        <time_frame>6 weeks</time_frame>
        <population>Trial closed due to early stopping rule, patients were not analyzed as there were only 3 patients enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A</title>
            <description>SUBATM-itraconazole 200 mg BID, Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then SUBATM-itraconazole 200 mg BID alone.&#xD;
Arm A: Experimental Arm</description>
          </group>
          <group group_id="O2">
            <title>Arm B</title>
            <description>Arm B = Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then Best supportive care.&#xD;
Arm B: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rates</title>
          <description>Per response evaluation criteria in solid tumors criteria</description>
          <population>Trial closed due to early stopping rule, patients were not analyzed as there were only 3 patients enrolled.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Blood Flow.</title>
        <description>To assess the changes in tumor blood flow as measured by contrast enhanced MRI scanning in patients with metastatic squamous non-small cell lung cancer treated with cisplatin and gemcitabine with or without SUBATM-itraconazole.</description>
        <time_frame>6 weeks.</time_frame>
        <population>Study closed due to early stopping rule. There were only 3 patients enrolled which were therefore not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cisplatin + Gemcitabine With SUBATM-itraconazole</title>
            <description>SUBATM-itraconazole 200 mg BID, Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then SUBATM-itraconazole 200 mg BID alone.&#xD;
Arm A: Experimental Arm</description>
          </group>
          <group group_id="O2">
            <title>Cisplatin + Gemcitabine</title>
            <description>Arm B = Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then Best supportive care.&#xD;
Arm B: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Blood Flow.</title>
          <description>To assess the changes in tumor blood flow as measured by contrast enhanced MRI scanning in patients with metastatic squamous non-small cell lung cancer treated with cisplatin and gemcitabine with or without SUBATM-itraconazole.</description>
          <population>Study closed due to early stopping rule. There were only 3 patients enrolled which were therefore not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Progression</title>
        <description>To determine the median time to progression and median duration of survival of patients with metastatic squamous non-small cell lung cancer treated with cisplatin and gemcitabine with or without SUBATM-itraconazole.</description>
        <time_frame>2 years.</time_frame>
        <population>Study closed due to early stopping rule. There were only 3 patients enrolled which were therefore not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cisplatin + Gemcitabine With SUBATM-itraconazole</title>
            <description>SUBATM-itraconazole 200 mg BID, Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then SUBATM-itraconazole 200 mg BID alone.&#xD;
Cisplatin + Gemcitabine with SUBATM-itraconazole: Experimental Arm</description>
          </group>
          <group group_id="O2">
            <title>Cisplatin + Gemcitabine</title>
            <description>Arm B = Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then Best supportive care.&#xD;
Cisplatin + Gemcitabine: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Progression</title>
          <description>To determine the median time to progression and median duration of survival of patients with metastatic squamous non-small cell lung cancer treated with cisplatin and gemcitabine with or without SUBATM-itraconazole.</description>
          <population>Study closed due to early stopping rule. There were only 3 patients enrolled which were therefore not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Effects</title>
        <description>To characterize the adverse effects of cisplatin and gemcitabine with or without SUBATM-itraconazole in this patient population.</description>
        <time_frame>2 years.</time_frame>
        <population>Study closed due to early stopping rule. There were only 3 patients enrolled which were therefore not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cisplatin + Gemcitabine With SUBATM-itraconazole</title>
            <description>SUBATM-itraconazole 200 mg BID, Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then SUBATM-itraconazole 200 mg BID alone.&#xD;
Arm A: Experimental Arm</description>
          </group>
          <group group_id="O2">
            <title>Cisplatin + Gemcitabine</title>
            <description>Arm B = Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then Best supportive care.&#xD;
Arm B: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effects</title>
          <description>To characterize the adverse effects of cisplatin and gemcitabine with or without SUBATM-itraconazole in this patient population.</description>
          <population>Study closed due to early stopping rule. There were only 3 patients enrolled which were therefore not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Itraconazole Exposure Parameters</title>
        <description>To correlate itraconazole exposure parameters with median time to progression and median survival in this patient population.</description>
        <time_frame>2 years.</time_frame>
        <population>Study closed due to early stopping rule. There were only 3 patients enrolled which were therefore not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cisplatin + Gemcitabine With SUBATM-itraconazole</title>
            <description>SUBATM-itraconazole 200 mg BID, Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then SUBATM-itraconazole 200 mg BID alone.&#xD;
Arm A: Experimental Arm</description>
          </group>
          <group group_id="O2">
            <title>Cisplatin + Gemcitabine</title>
            <description>Arm B = Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then Best supportive care.&#xD;
Arm B: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Itraconazole Exposure Parameters</title>
          <description>To correlate itraconazole exposure parameters with median time to progression and median survival in this patient population.</description>
          <population>Study closed due to early stopping rule. There were only 3 patients enrolled which were therefore not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Necrosis</title>
        <description>To assess changes in tumor necrosis in response to cisplatin and gemcitabine with or without SUBATM-itraconazole.</description>
        <time_frame>2 years.</time_frame>
        <population>Study closed due to early stopping rule. There were only 3 patients enrolled which were therefore not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cisplatin + Gemcitabine With SUBATM-itraconazole</title>
            <description>SUBATM-itraconazole 200 mg BID, Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then SUBATM-itraconazole 200 mg BID alone.&#xD;
Arm A: Experimental Arm</description>
          </group>
          <group group_id="O2">
            <title>Cisplatin + Gemcitabine</title>
            <description>Arm B = Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then Best supportive care.&#xD;
Arm B: Active Comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Necrosis</title>
          <description>To assess changes in tumor necrosis in response to cisplatin and gemcitabine with or without SUBATM-itraconazole.</description>
          <population>Study closed due to early stopping rule. There were only 3 patients enrolled which were therefore not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm A</title>
          <description>SUBATM-itraconazole 200 mg BID, Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then SUBATM-itraconazole 200 mg BID alone.&#xD;
Arm A: Experimental Arm</description>
        </group>
        <group group_id="E2">
          <title>Arm B</title>
          <description>Arm B = Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then Best supportive care.&#xD;
Arm B: Active Comparator</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronan Kelly, MD</name_or_title>
      <organization>SKCCC at Johns Hopkins</organization>
      <phone>443-287-0005</phone>
      <email>rkelly25@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

